Company intelligence / Profile preview
ANANDA Scientific
- Ownership
- Private
- Employees
- ~51
- Development stage
- Phase 2
Overview
ANANDA Scientific has six well-controlled Phase II clinical trials underway at leading academic institutions targeting neuropsychiatric conditions such as PTSD, OUD, social anxiety disorder, and smoking cessation. Their lead product Nantheia™ CBD uses a proprietary delivery technology to improve bioavailability and consistency of CBD absorption. Data from one PTSD phase II study and interim data from another are expected by June 2025; discussions with the FDA for a pivotal phase II/III study are planned for Q3.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Cannabinoids (notably cannabidiol/CBD)Plant-derived compoundsInvestigational drugs using proprietary delivery technology (Liquid Structure™)
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on ANANDA Scientific.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ANANDA Scientific.